On the public citation graph

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

https://doi.org/10.1093/annonc/mdx225
0 signed · 2434 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamadermatol.2015.2707openalex-snapshot
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
inferredcites →https://doi.org/10.1001/jamadermatol.2016.2226openalex-snapshot
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
inferredcites →https://doi.org/10.1001/jamaoncol.2015.4368openalex-snapshot
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
inferredcites →https://doi.org/10.1007/s00262-017-1962-6openalex-snapshot
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
inferredcites →https://doi.org/10.1007/s10620-009-0839-8openalex-snapshot
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
inferredcites →https://doi.org/10.1007/s10637-013-9939-6openalex-snapshot
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
inferredcites →https://doi.org/10.1016/j.cgh.2015.12.028openalex-snapshot
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
inferredcites →https://doi.org/10.1016/j.ctrv.2016.02.001openalex-snapshot
Management of toxicities of immune checkpoint inhibitors
inferredcites →https://doi.org/10.1016/j.ctrv.2016.02.003openalex-snapshot
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
inferredcites →https://doi.org/10.1016/j.currproblcancer.2016.12.004openalex-snapshot
Renal complications of immune checkpoint blockade
inferredcites →https://doi.org/10.1016/j.ejca.2016.02.010openalex-snapshot
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
inferredcites →https://doi.org/10.1016/j.ejca.2016.02.024openalex-snapshot
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
inferredcites →https://doi.org/10.1016/j.ejca.2016.02.025openalex-snapshot
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
inferredcites →https://doi.org/10.1016/j.jaad.2014.02.035openalex-snapshot
Ipilimumab in patients with cancer and the management of dermatologic adverse events
inferredcites →https://doi.org/10.1016/j.jtho.2017.03.011openalex-snapshot
Antineutrophil Cytoplasmic Antibody–Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report
inferredcites →https://doi.org/10.1016/j.kint.2016.04.008openalex-snapshot
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
inferredcites →https://doi.org/10.1016/s0016-5085(17)30956-3openalex-snapshot
Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade
inferredcites →https://doi.org/10.1016/s0140-6736(14)60958-2openalex-snapshot
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
inferredcites →https://doi.org/10.1016/s0140-6736(15)01281-7openalex-snapshot
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
inferredcites →https://doi.org/10.1016/s0959-8049(16)31822-6openalex-snapshot
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
inferredcites →https://doi.org/10.1016/s1470-2045(09)70334-1openalex-snapshot
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
inferredcites →https://doi.org/10.1016/s1470-2045(15)00083-2openalex-snapshot
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)70054-9openalex-snapshot
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)70076-8openalex-snapshot
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30126-7openalex-snapshot
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30366-7openalex-snapshot
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
inferredcites →https://doi.org/10.1038/bjc.2016.107openalex-snapshot
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
inferredcites →https://doi.org/10.1038/ncomms10391openalex-snapshot
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
inferredcites →https://doi.org/10.1038/nrclinonc.2016.58openalex-snapshot
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
inferredcites →https://doi.org/10.1056/nejmc1505197openalex-snapshot
Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
inferredcites →https://doi.org/10.1056/nejmc1509268openalex-snapshot
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
inferredcites →https://doi.org/10.1056/nejmoa1412082openalex-snapshot
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-snapshot
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot
Pembrolizumab versus Ipilimumab in Advanced Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1609214openalex-snapshot
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1056/nejmoa1611299openalex-snapshot
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
inferredcites →https://doi.org/10.1080/2162402x.2015.1128611openalex-snapshot
Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis
inferredcites →https://doi.org/10.1086/321805openalex-snapshot
Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
inferredcites →https://doi.org/10.1093/annonc/mdv383openalex-snapshot
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
inferredcites →https://doi.org/10.1093/annonc/mdv623openalex-snapshot
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
inferredcites →https://doi.org/10.1093/annonc/mdw443openalex-snapshot
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
inferredcites →https://doi.org/10.1093/annonc/mdw640openalex-snapshot
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
inferredcites →https://doi.org/10.1093/annonc/mdx108openalex-snapshot
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
inferredcites →https://doi.org/10.1093/annonc/mdx177openalex-snapshot
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
inferredcites →https://doi.org/10.1093/ecco-jcc/jjv227openalex-snapshot
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
inferredcites →https://doi.org/10.1093/ecco-jcc/jjx002.440openalex-snapshot
P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
inferredcites →https://doi.org/10.1097/01.cji.0000208259.73167.58openalex-snapshot
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
inferredcites →https://doi.org/10.1097/cco.0000000000000290openalex-snapshot
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
inferredcites →https://doi.org/10.1097/cco.0000000000000293openalex-snapshot
Endocrinological side-effects of immune checkpoint inhibitors
inferredcites →https://doi.org/10.1097/cco.0000000000000296openalex-snapshot
Ocular and orbital side-effects of checkpoint inhibitors: a review article
inferredcites →https://doi.org/10.1097/dad.0000000000000688openalex-snapshot
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
inferredcites →https://doi.org/10.1097/pas.0000000000000453openalex-snapshot
Ipilimumab-associated Hepatitis
inferredcites →https://doi.org/10.1111/apt.13281openalex-snapshot
Systematic review: colitis associated with anti‐ CTLA ‐4 therapy
inferredcites →https://doi.org/10.1111/cup.12858openalex-snapshot
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
inferredcites →https://doi.org/10.1111/his.13118openalex-snapshot
PD ‐1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
inferredcites →https://doi.org/10.1126/scitranslmed.3008002openalex-snapshot
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1024openalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-2471openalex-snapshot
Infliximab for IPILIMUMAB-Related Colitis—Letter
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-0712openalex-snapshot
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
inferredcites →https://doi.org/10.1158/2326-6066.cir-15-0102openalex-snapshot
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
inferredcites →https://doi.org/10.1159/000161122openalex-snapshot
Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
inferredcites →https://doi.org/10.1159/000452296openalex-snapshot
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
inferredcites →https://doi.org/10.1161/circheartfailure.116.003514openalex-snapshot
Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
inferredcites →https://doi.org/10.1186/s40425-015-0057-1openalex-snapshot
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
inferredcites →https://doi.org/10.1186/s40425-016-0157-6openalex-snapshot
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
inferredcites →https://doi.org/10.1186/s40425-017-0210-0openalex-snapshot
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
inferredcites →https://doi.org/10.1200/jco.2005.04.5716openalex-snapshot
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
inferredcites →https://doi.org/10.1200/jco.2010.32.2206openalex-snapshot
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
inferredcites →https://doi.org/10.1200/jco.2011.37.9693openalex-snapshot
Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
inferredcites →https://doi.org/10.1200/jco.2011.39.3298openalex-snapshot
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
inferredcites →https://doi.org/10.1200/jco.2012.41.6750openalex-snapshot
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
inferredcites →https://doi.org/10.1200/jco.2013.53.0105openalex-snapshot
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
inferredcites →https://doi.org/10.1200/jco.2014.58.3708openalex-snapshot
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2015.60.8448openalex-snapshot
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
inferredcites →https://doi.org/10.1200/jco.2015.66.1389openalex-snapshot
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
inferredcites →https://doi.org/10.1200/jco.2016.68.2005openalex-snapshot
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
inferredcites →https://doi.org/10.14694/edbook_am.2015.35.76openalex-snapshot
Managing Immune Checkpoint-Blocking Antibody Side Effects
inferredcites →https://doi.org/10.2337/dc15-0889openalex-snapshot
Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4201024openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4612630openalex-extracted
inferred← citeshttps://doi.org/10.1001/jamadermatol.2022.1624openalex-snapshot
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.4427openalex-snapshot
Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.45596openalex-snapshot
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.2668openalex-snapshot
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
inferred← citeshttps://doi.org/10.1001/jamaneurol.2021.0249openalex-snapshot
Encephalitis Induced by Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4604openalex-snapshot
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2019.1022openalex-snapshot
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.0726openalex-snapshot
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.3595openalex-snapshot
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.4342openalex-snapshot
Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer
inferred← citeshttps://doi.org/10.1001/jamaoncol.2022.5041openalex-snapshot
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2022.7711openalex-snapshot
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm134.pub2openalex-snapshot
Respiratory Complications
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm141.pub2openalex-snapshot
Oncologic Emergencies
inferred← citeshttps://doi.org/10.1002/9781119564690.ch13openalex-snapshot
New Emerging Biotherapies
inferred← citeshttps://doi.org/10.1002/9781119784395.ch13openalex-snapshot
Managing Complications of Cancer
inferred← citeshttps://doi.org/10.1002/9781119802181.ch14openalex-snapshot
Oncology
inferred← citeshttps://doi.org/10.1002/9781119858430.ch18openalex-snapshot
Autoimmune Phenomena in Cancer Patients Treated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1002/adma.202401667openalex-snapshot
Grooved Microneedle Patch Augments Adoptive T Cell Therapy Against Solid Tumors via Diverting Regulatory T Cells
inferred← citeshttps://doi.org/10.1002/adma.202412340openalex-snapshot
Reversing Immune Checkpoint Inhibitor–Associated Cardiotoxicity via Bioorthogonal Metabolic Engineering–Driven Extracellular Vesicle Redirecting
inferred← citeshttps://doi.org/10.1002/aid2.13303openalex-snapshot
Atezolizumab‐associated colitis mimic inflammatory bowel disease: A case report
inferred← citeshttps://doi.org/10.1002/ana.25708openalex-snapshot
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
inferred← citeshttps://doi.org/10.1002/ange.202310694openalex-snapshot
Recent Advances in the Development of Non‐Invasive Imaging Probes for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/anie.202310694openalex-snapshot
Recent Advances in the Development of Non‐Invasive Imaging Probes for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/art.41068openalex-snapshot
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
inferred← citeshttps://doi.org/10.1002/art.41587openalex-snapshot
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
inferred← citeshttps://doi.org/10.1002/art.41949openalex-snapshot
Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer
inferred← citeshttps://doi.org/10.1002/art.42743openalex-snapshot
Inhibiting the Inhibitor in Synovial Macrophages and Cancer Immunotherapy–Associated Inflammatory Arthritis
inferred← citeshttps://doi.org/10.1002/bco2.335openalex-snapshot
Immune checkpoint inhibitors in high‐grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation
inferred← citeshttps://doi.org/10.1002/cac2.12539openalex-snapshot
Immunologic tumor microenvironment modulators for turning cold tumors hot
inferred← citeshttps://doi.org/10.1002/cac2.12587openalex-snapshot
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
inferred← citeshttps://doi.org/10.1002/cam4.3378openalex-snapshot
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study
inferred← citeshttps://doi.org/10.1002/cam4.3600openalex-snapshot
Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
inferred← citeshttps://doi.org/10.1002/cam4.4040openalex-snapshot
High‐dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors––A nationwide register‐based cohort study
inferred← citeshttps://doi.org/10.1002/cam4.5357openalex-snapshot
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
inferred← citeshttps://doi.org/10.1002/cam4.6449openalex-snapshot
Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study
inferred← citeshttps://doi.org/10.1002/cam4.6647openalex-snapshot
Chemotherapy in pediatric brain tumor and the challenge of the blood–brain barrier
inferred← citeshttps://doi.org/10.1002/cam4.70080openalex-snapshot
Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study
inferred← citeshttps://doi.org/10.1002/cam4.71603openalex-snapshot
Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐ PD ‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital
inferred← citeshttps://doi.org/10.1002/ccr3.2534openalex-snapshot
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature
inferred← citeshttps://doi.org/10.1002/ccr3.3597openalex-snapshot
Successful mycophenolate mofetil treatment of a patient with severe steroid‐refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer
inferred← citeshttps://doi.org/10.1002/ccr3.3973openalex-snapshot
Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report
inferred← citeshttps://doi.org/10.1002/ccr3.5174openalex-snapshot
Nivolumab‐induced liver injury with a steroid‐refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report
inferred← citeshttps://doi.org/10.1002/ccr3.6392openalex-snapshot
Cancer patients and targeted therapy during COVID‐19 pandemic: A descriptive case series study
inferred← citeshttps://doi.org/10.1002/ccr3.70756openalex-snapshot
Tirelizumab‐Induced Immune Encephalitis: A Case Report
inferred← citeshttps://doi.org/10.1002/ccr3.9153openalex-snapshot
A case report of immune checkpoint inhibitor‐related myositis and cholangitis induced by pembrolizumab
inferred← citeshttps://doi.org/10.1002/cld.1241openalex-snapshot
Immune checkpoint inhibitor–related liver toxicity
inferred← citeshttps://doi.org/10.1002/cncr.31243openalex-snapshot
Current developments in immunotherapy in the treatment of multiple myeloma
inferred← citeshttps://doi.org/10.1002/cncr.31795openalex-snapshot
Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1002/cncr.33165openalex-snapshot
Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
inferred← citeshttps://doi.org/10.1002/cncr.34244openalex-snapshot
Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity
inferred← citeshttps://doi.org/10.1002/cncr.34543openalex-snapshot
Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course
inferred← citeshttps://doi.org/10.1002/cncr.35300openalex-snapshot
Electronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial
inferred← citeshttps://doi.org/10.1002/cnr2.1624openalex-snapshot
Mycophenolate mofetil for immune checkpoint inhibitor‐related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review
inferred← citeshttps://doi.org/10.1002/cnr2.1721openalex-snapshot
A case of HCC successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy
inferred← citeshttps://doi.org/10.1002/cnr2.1778openalex-snapshot
Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint‐inhibitor pneumonitis: A case report and literature review
inferred← citeshttps://doi.org/10.1002/cpdd.1446openalex-snapshot
Clinical Implications of Co‐administering Apixaban with Key Interacting Medications
inferred← citeshttps://doi.org/10.1002/cpt.3285openalex-snapshot
“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents
inferred← citeshttps://doi.org/10.1002/ctm2.1613openalex-snapshot
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
inferred← citeshttps://doi.org/10.1002/dmrr.3366openalex-snapshot
Diabetes mellitus induced by immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1002/edm2.246openalex-snapshot
Rethinking the management of immune checkpoint inhibitor‐related adrenal insufficiency in cancer patients during the COVID‐19 pandemic
inferred← citeshttps://doi.org/10.1002/ehf2.14330openalex-snapshot
Acute Myocarditis with Transient Myocardial Thickening in Two Oncologic Patients Treated with Anti-GD2 Immunotherapy
inferred← citeshttps://doi.org/10.1002/ejhf.1957openalex-snapshot
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
inferred← citeshttps://doi.org/10.1002/ejhf.2329openalex-snapshot
Cardiac immune‐related adverse events: an immune‐cardio‐oncology puzzle
inferred← citeshttps://doi.org/10.1002/ejhf.3340openalex-snapshot
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
inferred← citeshttps://doi.org/10.1002/emp2.12209openalex-snapshot
Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department
inferred← citeshttps://doi.org/10.1002/hed.25911openalex-snapshot
Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review
inferred← citeshttps://doi.org/10.1002/hed.26455openalex-snapshot
Recurrent audiovestibular dysfunction and associated neurological immune‐related adverse events in a melanoma patient treated with nivolumab and ipilimumab
inferred← citeshttps://doi.org/10.1002/hep.31227openalex-snapshot
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
inferred← citeshttps://doi.org/10.1002/hep.32215openalex-snapshot
Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis
inferred← citeshttps://doi.org/10.1002/hep.32447openalex-snapshot
Emerging immunotherapy for HCC: A guide for hepatologists
inferred← citeshttps://doi.org/10.1002/hep.32553openalex-snapshot
Reply
inferred← citeshttps://doi.org/10.1002/ijc.32080openalex-snapshot
Differential effects of corticosteroids and anti‐TNF on tumor‐specific immune responses: implications for the management of irAEs
inferred← citeshttps://doi.org/10.1002/ijc.33266openalex-snapshot
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
inferred← citeshttps://doi.org/10.1002/ijc.33415openalex-snapshot
Targeting CTLA ‐4 in cancer: Is it the ideal companion for PD ‐1 blockade immunotherapy combinations?
inferred← citeshttps://doi.org/10.1002/ijc.70307openalex-snapshot
Organ‐sparing strategies in patients with MSI / dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making
inferred← citeshttps://doi.org/10.1002/iju5.12231openalex-snapshot
Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma
inferred← citeshttps://doi.org/10.1002/iju5.12338openalex-snapshot
Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
inferred← citeshttps://doi.org/10.1002/jac5.1531openalex-snapshot
Impact of pharmacists on identification of immune checkpoint inhibitor toxicities
inferred← citeshttps://doi.org/10.1002/jcph.1291openalex-snapshot
Rash and Pruritus With PD‐1 Inhibitors in Cancer Patients: A Meta‐Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1002/jcu.22975openalex-snapshot
A case of immune checkpoint inhibitor‐associated gastroenteritis detected by ultrasonography
inferred← citeshttps://doi.org/10.1002/jgh3.12392openalex-snapshot
Immune checkpoint inhibitor‐induced enteritis assessed using capsule endoscopy
inferred← citeshttps://doi.org/10.1002/jgh3.12737openalex-snapshot
Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection
inferred← citeshttps://doi.org/10.1002/jvc2.70294openalex-snapshot
Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective
inferred← citeshttps://doi.org/10.1002/lary.28038openalex-snapshot
Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer
inferred← citeshttps://doi.org/10.1002/lci2.38openalex-snapshot
Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/mdr2.70019openalex-snapshot
The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events
inferred← citeshttps://doi.org/10.1002/med.70093openalex-snapshot
Hepatotoxicity in the Era of Precision Medicine: Toxicological Mechanisms and Management of Immune and Cell Therapy‐Induced Liver Injury
inferred← citeshttps://doi.org/10.1002/med4.51openalex-snapshot
Modifying the electrical, optical, and magnetic properties of cancer cells: A comprehensive approach for cancer management
inferred← citeshttps://doi.org/10.1002/mog2.70030openalex-snapshot
Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics
inferred← citeshttps://doi.org/10.1002/msp2.50openalex-snapshot
Update on immunotherapy‐mediated colitis: Clinical features, mechanisms, and management
inferred← citeshttps://doi.org/10.1002/onco.13755openalex-snapshot
An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/path.5989openalex-snapshot
Experimental investigation of skin toxicity after immune checkpoint inhibition in combination with radiation therapy
inferred← citeshttps://doi.org/10.1002/pdi.2276openalex-snapshot
Immune checkpoint inhibitors and diabetes
inferred← citeshttps://doi.org/10.1002/phar.70110openalex-snapshot
Cancer Therapy‐Induced Cardiotoxicity: A Narrative Review
inferred← citeshttps://doi.org/10.1002/pon.6093openalex-snapshot
A new landscape in illness uncertainty: A systematic review and thematic synthesis of the experience of uncertainty in patients with advanced cancer receiving immunotherapy or targeted therapy
inferred← citeshttps://doi.org/10.1007/164_2019_323openalex-snapshot
Monoclonal Antibodies: Past, Present and Future
inferred← citeshttps://doi.org/10.1007/16833_2022_80openalex-snapshot
An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis
inferred← citeshttps://doi.org/10.1007/978-3-030-05070-2_60openalex-snapshot
Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-16550-5_7openalex-snapshot
The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-21573-6_10053-1openalex-snapshot
Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/978-3-030-24593-1_13openalex-snapshot
Precision Medicine and Complexity
inferred← citeshttps://doi.org/10.1007/978-3-030-41008-7_13openalex-snapshot
Immune-Related Adverse Events: Pneumonitis
inferred← citeshttps://doi.org/10.1007/978-3-030-45347-3_17openalex-snapshot
Systemic Treatment in Advanced Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-50287-4_31openalex-snapshot
Hurdles in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-52021-2_19openalex-snapshot
Upper Tract Urothelial Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_19openalex-snapshot
Treatment Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-030-56051-5_57openalex-snapshot
Cutaneous Melanoma and Other Skin Cancers
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_10openalex-snapshot
Non-Rheumatic Immune-Related Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_13openalex-snapshot
Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-56824-5_9openalex-snapshot
Miscellaneous Rheumatic Syndromes
inferred← citeshttps://doi.org/10.1007/978-3-030-57401-7_10053openalex-snapshot
Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1007/978-3-030-58174-9_15openalex-snapshot
Industrial Perspective on Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-58846-5_20openalex-snapshot
Immunotherapy in Patients with mCRC
inferred← citeshttps://doi.org/10.1007/978-3-030-64009-5_10openalex-snapshot
Ipilimumab in Melanoma: An Evergreen Drug
inferred← citeshttps://doi.org/10.1007/978-3-030-65463-4_7openalex-snapshot
Imaging-Guided Palliative Procedures: Tendon and Bursa Injection
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_27openalex-snapshot
Diarrhea
inferred← citeshttps://doi.org/10.1007/978-3-030-67123-5_53openalex-snapshot
Toxicities of Novel Antineoplastic Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-68858-5_22openalex-snapshot
18F-FDG PET-CT in Treatment Response Evaluation in Cutaneous Malignant Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-74028-3_7openalex-snapshot
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-78648-9_10openalex-snapshot
Symptoms and Symptom Management in Survivorship Patients
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_13openalex-snapshot
Hepatobiliary and Pancreatic Adverse Events
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_14openalex-snapshot
Pulmonary Toxicities of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-79308-1_16openalex-snapshot
Renal Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-030-80546-3_18openalex-snapshot
Safety of Immune Checkpoint Inhibitors in the Peri-operative Setting
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_178-1openalex-snapshot
Checkpoint Blockade in Hematologic Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_215-1openalex-snapshot
Immunotherapy and Cancer: The Pharmacists’ Perspective
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_341-1openalex-snapshot
Diagnosis and Management of Toxicities Associated with Immunotherapy in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_346-1openalex-snapshot
A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_348-1openalex-snapshot
Endocrine Toxicities Related to Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-80962-1_349-1openalex-snapshot
Pulmonary Side Effects of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-82743-4_16openalex-snapshot
Oncology: Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-86510-8_10openalex-snapshot
Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-89162-6_22openalex-snapshot
Cutaneous Melanoma in Older Adults with Frailty
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-1openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_12-2openalex-snapshot
Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_2-1openalex-snapshot
Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-93702-7_5-1openalex-snapshot
Gynecologic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-94110-9_11openalex-snapshot
Chemotherapy in Gynaecological Cancers and Newer Developments
inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_12openalex-snapshot
Pancreas and Gallbladder
inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_14openalex-snapshot
Pulmonology (Lung)
inferred← citeshttps://doi.org/10.1007/978-3-031-00241-0_7openalex-snapshot
Hepatology (Liver and Bile Duct)
inferred← citeshttps://doi.org/10.1007/978-3-031-05494-5_7openalex-snapshot
Diagnostic Applications of Nuclear Medicine: Lymphomas
inferred← citeshttps://doi.org/10.1007/978-3-031-11363-5_13openalex-snapshot
Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-21040-2_26openalex-snapshot
Iatrogenic Conditions
inferred← citeshttps://doi.org/10.1007/978-3-031-22265-8_10openalex-snapshot
Non-surgical Cancer Treatments
inferred← citeshttps://doi.org/10.1007/978-3-031-23394-4_10openalex-snapshot
Early and Acute Complications and the Principles of HSCT Nursing Care
inferred← citeshttps://doi.org/10.1007/978-3-031-38412-7_11openalex-snapshot
Pulmonary Complications of Lung Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-3-031-60855-1_13openalex-snapshot
Nephrological and Rheumatic Complications of Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_31openalex-snapshot
Autoimmune Hemolytic Anemia Post Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_43openalex-snapshot
Optic Neuritis Post Immune Checkpoint Inhibitor Therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_44openalex-snapshot
Uveitis Post Immune Checkpoint Inhibitor Therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-83533-9_56openalex-snapshot
A Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy
inferred← citeshttps://doi.org/10.1007/978-3-032-00765-0_178openalex-snapshot
Checkpoint Blockade in Hematologic Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-032-00765-0_346openalex-snapshot
A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-032-00767-4_215openalex-snapshot
Immunotherapy and Cancer: The Pharmacists’ Perspective
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_341openalex-snapshot
Diagnosis and Management of Toxicities Associated with Immunotherapy in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_348openalex-snapshot
Endocrine Toxicities Related to Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-032-00775-9_349openalex-snapshot
Pulmonary Side Effects of Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-032-14103-3_22openalex-snapshot
Quantitative Imaging in Response Assessment of Lung Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_7-2openalex-snapshot
Diagnostic Applications of Nuclear Medicine: Lymphomas
inferred← citeshttps://doi.org/10.1007/978-3-319-46029-1_60-1openalex-snapshot
Managing Checkpoint Inhibitor Symptoms and Toxicity
inferred← citeshttps://doi.org/10.1007/978-3-319-76457-3_5openalex-snapshot
Immunotherapy: New Challenges for Nursing
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_54-1openalex-snapshot
Checkpoint-Inhibitoren
inferred← citeshttps://doi.org/10.1007/978-3-662-54652-9_26-1openalex-snapshot
Prophylaxe und Therapie von Komplikationen der systemischen Tumortherapie
inferred← citeshttps://doi.org/10.1007/978-3-662-54652-9_48-1openalex-snapshot
Behandlungspläne medikamentöser Therapie des Harnblasenkarzinoms
inferred← citeshttps://doi.org/10.1007/978-3-662-59911-2_16openalex-snapshot
Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms
inferred← citeshttps://doi.org/10.1007/978-3-662-66606-7_5openalex-snapshot
Veränderungen der Haut
inferred← citeshttps://doi.org/10.1007/978-3-662-67417-8_8openalex-snapshot
Medikamentöse Tumortherapie
inferred← citeshttps://doi.org/10.1007/978-981-15-7586-0_8openalex-snapshot
Pharmacologic Modulation of the Immune Response Against Tumours in the Elderly
inferred← citeshttps://doi.org/10.1007/978-981-15-9038-2_9openalex-snapshot
Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics
inferred← citeshttps://doi.org/10.1007/978-981-16-8845-4_21openalex-snapshot
Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-981-16-9929-0_25openalex-snapshot
Management of Complications and Toxicities Related to Chemotherapy in ICU
inferred← citeshttps://doi.org/10.1007/978-981-99-7141-1_19openalex-snapshot
Future Perspectives of Cancer Immunotherapy for the Treatment of Lung Cancer
inferred← citeshttps://doi.org/10.1007/s00018-025-05744-3openalex-snapshot
Mechanisms of drug induced liver injury
inferred← citeshttps://doi.org/10.1007/s00059-020-04902-6openalex-snapshot
Neue onkologische Therapien und ihre kardiovaskulären Risiken
inferred← citeshttps://doi.org/10.1007/s00063-018-0521-zopenalex-snapshot
Diagnostik und Therapie von immunvermittelten Nebenwirkungen durch Checkpointinhibitoren in der Intensivmedizin
inferred← citeshttps://doi.org/10.1007/s00066-022-01973-8openalex-snapshot
DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment
inferred← citeshttps://doi.org/10.1007/s00092-022-5501-1openalex-snapshot
Immunbedingte Toxizitäten behandeln
inferred← citeshttps://doi.org/10.1007/s00103-020-03221-9openalex-snapshot
Checkpointinhibitoren in der Tumortherapie
inferred← citeshttps://doi.org/10.1007/s00105-019-04496-zopenalex-snapshot
Supportivtherapie und Nebenwirkungsmanagement in der Dermatoonkologie
inferred← citeshttps://doi.org/10.1007/s00108-021-01121-xopenalex-snapshot
[63/f-Dyspnea of unknown origin : Preparation for the medical specialist examination: part 67].
inferred← citeshttps://doi.org/10.1007/s00108-021-01259-8openalex-snapshot
Was muss der Internist bei Patienten unter Biologikabehandlung beachten?
inferred← citeshttps://doi.org/10.1007/s00108-022-01454-1openalex-snapshot
Krebsmedizin im Wandel – Wo steht die Psychoonkologie?
inferred← citeshttps://doi.org/10.1007/s00115-021-01223-9openalex-snapshot
Tumortherapieassoziierte neurologische Symptome
inferred← citeshttps://doi.org/10.1007/s00120-021-01550-4openalex-snapshot
Nebenwirkungen der Immun-Checkpoint-Inhibitor-Therapie urologischer Tumoren
inferred← citeshttps://doi.org/10.1007/s00129-020-04577-4openalex-snapshot
Immuntherapeutische Therapieansätze – ein Überblick
inferred← citeshttps://doi.org/10.1007/s00129-020-04580-9openalex-snapshot
Überblick Nebenwirkungsmanagement moderner Immuntherapien
inferred← citeshttps://doi.org/10.1007/s00129-022-04941-6openalex-snapshot
Nebenwirkungsmanagement immunonkologischer Therapien – was gibt es zu beachten?
inferred← citeshttps://doi.org/10.1007/s00129-023-05055-3openalex-snapshot
Immuncheckpointinhibitoren in der Gynäkologie: Was, wann und bei wem?
inferred← citeshttps://doi.org/10.1007/s00129-023-05109-6openalex-snapshot
Immuntherapie in der gynäkologischen Onkologie und Senologie
inferred← citeshttps://doi.org/10.1007/s00134-019-05650-wopenalex-snapshot
Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases
inferred← citeshttps://doi.org/10.1007/s00261-019-02334-3openalex-snapshot
Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy
inferred← citeshttps://doi.org/10.1007/s00261-020-02531-5openalex-snapshot
Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
inferred← citeshttps://doi.org/10.1007/s00261-020-02837-4openalex-snapshot
CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor‐specific therapies
inferred← citeshttps://doi.org/10.1007/s00261-021-02986-0openalex-snapshot
CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.
inferred← citeshttps://doi.org/10.1007/s00261-021-03024-9openalex-snapshot
Chemotherapy-induced bowel ischemia: diagnostic imaging overview
inferred← citeshttps://doi.org/10.1007/s00262-018-2159-3openalex-snapshot
Immune-mediated cholangitis: is it always nivolumab’s fault?
showing the first 200 of 2348
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.